GlobeNewswire·Nov 9, 2026, 4:01 PM ET

MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights

Enrollment in the pivotal Phase 3 oPTimize trial of once-weekly canvuparatide began in August 2026 for approximately 160 adults with chronic hypoparathyroidism.
Unblinded 12-week MAD data for MBX 4291, a GLP-1/GIP co-agonist prodrug designed for once-monthly dosing, is expected in Q4 2026.
Preclinical data for MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug, was accepted for presentation at ObesityWeek 2026 in Washington, D.C.
IND-enabling studies are ongoing for MBX 5765, an amycretin prodrug candidate designed for once-monthly dosing.
Peter Radovich was appointed to the Board of Directors in October 2026, bringing over 20 years of biopharmaceutical industry experience.
Jeff Held was appointed Chief Legal Officer in September 2026 with over 30 years of legal \& executive leadership experience.
Cash, cash equivalents, \& marketable securities totaled $481.6 million as of September 30, 2026, with funds expected to support operations into 2029.
Research \& development expenses for the third quarter of 2026 were $32.0 million, driven by start-up costs for the canvuparatide Phase 3 trial.
General \& administrative expenses for the third quarter of 2026 were $34.3 million, including $20.8 million in stock-based compensation related to the former CEO.
The net loss for the three months ended September 30, 2026, was $62.4 million compared to $21.6 million in the same period of 2025.